Search clinical trials for: graft-versus-host disease

Total 381028 results

Dana-Farber Cancer Institute
National Cancer Institute (NCI)

Completed

Methylprednisolone With or Without Daclizumab in Treating Patients With Acute Graft-Versus-Host Disease

Graft Versus Host Disease

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor

Lymphoma | Acute Myeloid Leukemia | Myelodysplastic Syndromes | Chronic Lymphocytic Leukemia | Chronic Myeloid Leukemia | Acute Lymphocytic Leukemia | Aplastic Anemia | Hodgkin's Disease | Biphenotypic Leukemia | Plasma Cell Neoplasms

United States
University of Rochester

Terminated

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Mantle Cell Lymphoma

Lymphoma | Graft Versus Host Disease

United States
Sheba Medical Center

Unknown

Carfilzomib for the Prevention of Graft Versus Host Disease

Graft-versus-host Disease

Israel
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors

Sarcoma

United States
H. Lee Moffitt Cancer Center and Research Institute

Completed

Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation

Acute Graft Versus Host Disease

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Graft-Versus-Host Disease in Treating Patients With Recurrent or Refractory Lymphoma or Hodgkin's Disease

Lymphoma | Graft Versus Host Disease

United States
The Affiliated Hospital of the Chinese Academy...

Completed

HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

Acute Myeloid Leukemia

China
European Society for Blood and Marrow Transplantation
Novartis

Terminated

Myfortic - Treatment for Extensive cGvHD

Graft vs Host Disease

Switzerland, Spain, Sweden, Italy, France, Germany, Netherlands, Turkey
University of Michigan

Completed

Recombinant Human Keratinocyte Growth Factor in Unrelated and Related Transplants

Graft Versus Host Disease

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease
Mesoblast International Sàrl
National Cancer Institute (NCI)

Withdrawn

OTI-010 for Graft-Versus-Host Disease Prophylaxis in Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation for Hematologic Malignancies

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous Condition | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms | Secondary Myelofibrosis

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Terminated

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Graft Versus Host Disease

United States
Eisai Inc.

Terminated

A Study of Eritoran (E5564) Administered IV Over 14 Days Prior to and During Bone Marrow Engraftment in BMT Patients Who Have Received Myeloablative Conditioning Treatment and Are Receiving Bone Marrow or Stem Cells From Matched Related Donors

Leukemia

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Prevention of Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Cancer

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
The Canadian Blood and Marrow Transplant Group
National Cancer Institute (NCI)

Completed

Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Graft Versus Host Disease | Secondary Myelofibrosis

Australia, Canada, United States, New Zealand, Saudi Arabia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Hydroxychloroquine in Treating Patients With Newly Diagnosed Chronic Graft-Versus-Host Disease

Graft Versus Host Disease

United States, Canada, Australia, Switzerland, Puerto Rico, New Zealand
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Fludarabine in Treating Patients With Steroid-Resistant Chronic Graft- Versus-Host Disease

Graft Versus Host Disease
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

Leukemia | Graft Versus Host Disease

United States
St. Bartholomew's Hospital

Unknown

Early Diagnosis of Aspergillosis in Patients at High Risk of Fungal Infection Caused by Treatment for Hematologic Cancer or Other Disease

Myelodysplastic Syndromes | Leukemia | Infection | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United Kingdom
University Hospital Birmingham

Unknown

T-Lymphocyte Infusion or Standard Therapy in Treating Patients at Risk of Cytomegalovirus Infection After a Donor Stem Cell Transplant

Graft Versus Host Disease | Nonneoplastic Condition

United Kingdom
Dana-Farber Cancer Institute
Massachusetts General Hospital; Beth Israel Deaconess Medical Center; Emory University and other collaborators

Completed

Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies

Sickle Cell Disease | Hemoglobinopathies | Thalassemia

United States
Chimeric Therapies

Completed

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Beclomethasone Plus Prednisone in Treating Patients With Graft-Versus-Host Disease

Graft Versus Host Disease

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant

Cancer

United States
Martin, Paul
National Cancer Institute (NCI)

Terminated

Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD)

Cancer

United States, Canada
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease | Myelodysplastic/Myeloproliferative Neoplasms

United States
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Terminated

Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease
H. Lee Moffitt Cancer Center and Research Institute
National Cancer Institute (NCI)

Terminated

Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation

Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia

Myelodysplastic Syndromes | Leukemia | Graft Versus Host Disease

United States
Cytheris, Inc.

Completed

Safety Study of IL-7 in Recipients of a Hemopoietic Stem Cell Transplant Peripheral Blood Stem Cell Transplant

AML | MDS | CML

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Small Intestine Cancer | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Precancerous/Nonmalignant Condition

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Precancerous/Nonmalignant Condition

United States
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

G-CSF-Treated Donor Bone Marrow Transplant in Treating Patients With Hematologic Disorders

Sarcoma | Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
Dana-Farber Cancer Institute
National Cancer Institute (NCI); Beth Israel Deaconess Medical Center; Brigham...

Completed

Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant

Hematologic Malignancy

United States
Dana-Farber Cancer Institute
Brigham and Women's Hospital

Completed

CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation

Multiple Myeloma | Hodgkin's Lymphoma | AML | Hematologic Malignancy | NHL | CML | ALL

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
Fred Hutchinson Cancer Center

Completed

Graft-Versus-Host Disease Prevention in Treating Patients Who Are Undergoing Bone Marrow Transplantation

Lymphoma | Leukemia | Graft Versus Host Disease

United States
University Health Network, Toronto
Hoffmann-La Roche

Terminated

A Study of Rituximab Combined With Prednisone for the Initial Treatment of Chronic Graft Versus Host Disease (cGVHD)

Graft Versus Host Disease

Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Multiple Myeloma and Plasma Cell Neoplasm | Myelodysplastic/Myeloproliferative Diseases | Graft Versus Host Disease

United States
Roswell Park Cancer Institute

Completed

Compassionate Use of Beclomethasone in Treating Patients With Graft-Versus-Host Disease of the Gastrointestinal Tract

Graft Versus Host Disease

United States
Roswell Park Cancer Institute
National Cancer Institute (NCI)

Completed

Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases

Myelodysplastic Syndromes | Leukemia | Thymic Carcinoma | Graft Versus Host Disease

United States
Roswell Park Cancer Institute

Completed

Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Neuroblastoma | Graft Versus Host Disease

United States
Roswell Park Cancer Institute

Completed

Thalidomide in Treating Patients With Chronic Graft-Versus-Host Disease Following Bone Marrow Transplant

Unspecified Childhood Solid Tumor, Protocol Specific | Unspecified Adult Solid Tumor, Protocol Specific | Graft Versus Host Disease

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Terminated

Immunologic Diagnostic Blood Test in Predicting Side-Effects in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer or Other Diseases

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Myelodysplastic-Myeloproliferative Diseases | Neuroblastoma | Infection | Multiple Myeloma and Plasma Cell Neoplasm | Graft Versus Host Disease | Therapy-related Toxicity

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Donor Mesenchymal Stem Cell Infusion in Treating Patients With Acute or Chronic Graft-Versus-Host Disease After Undergoing a Donor Stem Cell Transplant

Cancer

United States

Search clinical trials for: graft-versus-host disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United States

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations